Proteasome inhibitors.

Area of Science:

• Oncology
• Pharmacology
• Hematology

Background:

• Bortezomib is a proteasome inhibitor approved for multiple myeloma and mantle cell lymphoma.
• It is used as third-line, second-line, and first-line therapy in multiple myeloma, alone or in combination.
• Its approval by the US FDA in 2003 marked a significant advancement in cancer treatment.

Purpose of the Study:

• To review current clinical research on bortezomib.
• To discuss adverse effects and patient resistance to bortezomib-based therapies.
• To explore bortezomib's applications in various diseases and new proteasome inhibitor developments.

Main Methods:

• Literature review of clinical research on bortezomib.
• Analysis of bortezomib's efficacy, safety, and resistance mechanisms.
• Review of emerging proteasome inhibitors and related therapies.

Main Results:

• Bortezomib has demonstrated efficacy in multiple myeloma and mantle cell lymphoma across different treatment lines.
• Adverse effects and patient resistance are key challenges in bortezomib therapy.
• Ongoing research focuses on overcoming resistance and developing next-generation proteasome inhibitors.

Conclusions:

• Bortezomib remains a crucial therapeutic agent for multiple myeloma and mantle cell lymphoma.
• Understanding and addressing bortezomib resistance is essential for improving patient outcomes.
• Advancements in proteasome inhibitor research promise more effective treatments for these hematological malignancies.